VIR News and Press, Vir Biotechnology Inc. From 08/21/23

2023-08-21 05:04:54 ET Summary Vir Biotechnology recently released its Q2 2023 earnings and has experienced a drop in stock price due to a setback in its Phase 2 trials. The company has a diverse clinical pipeline focused on infectious diseases and respiratory conditions, with sig...

2023-08-03 16:09:55 ET Vir Biotechnology press release ( NASDAQ: VIR ): Q2 EPS of -$1.45 may not be comparable to consensus of -$1.19. Revenue of $3.8M misses by $18.59M . $1.9 billion in cash, cash equivalents and investments as of June 30, 2023 For further ...

– Phase 2 data readouts from ongoing chronic hepatitis B and chronic hepatitis delta programs on track for Q4 2023 – – Increased focus on proprietary antibody platform and discontinuation of Vir’s innate immunity small molecule platform – ...

2023-07-26 23:18:28 ET Summary Intellia is a pipeline-stage firm, leveraging gene-editing technology to develop therapies for rare diseases. NTLA is on track toward key data and regulatory catalysts. Early clinical data in HAE and ATTR have provided solid validation for Intellia's...

SAN FRANCISCO, July 26, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2023 on August 3, 2023. The Company will host a conference call at 4:30 p.m. Easter...

2023-07-26 09:46:46 ET GSK ( NYSE: GSK ) raised its full-year outlook with its financials for Q2 2023, which stood ahead of expectations on Wednesday amid strong sales results for its vaccine business despite headwinds to the company’s COVID treatments. The company po...

2023-07-21 09:48:40 ET Summary Vir Biotechnology's stock fell by 44% following disappointing Phase 2 trial results for its influenza A preventive treatment, VIR-2482. Despite a decrease in total revenues from $1.2 billion in Q1 2022 to $63 million in Q1 2023, Vir maintains a healt...

2023-07-20 11:31:00 ET Shares of Vir Biotechnology (NASDAQ: VIR) were down more than 44% as of 10:45 a.m. on Thursday after the company announced phase 2 trial results for an influenza A therapy candidate. The stock is down more than 49% so far this year. Vir focuses on immunolo...

2023-07-20 10:23:14 ET Gainers: PainReform ( PRFX ) +55% . T2 Biosystems ( TTOO ) +19% . Inotiv ( NOTV ) +15% . Tarsus Pharmaceuticals ( TARS ) +14% . Nanobiotix ( NBTX ) +11% . Losers: Vir Biotechnology ( VIR ) ...

2023-07-20 08:46:16 ET Vir Biotechnology ( NASDAQ: VIR ) fell ~40% pre-market Thursday after the company said that its Phase 2 trial for VIR-2482, a monoclonal antibody targeted at the prevention of influenza A, did not meet its main goals. In terms of its primary endpoint, ...